Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Total Current Liabilities
All obligations due within one year.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 6.3% from a year ago
Total current liabilities stood at $15.95M at the end of Q1 FY2026, up 6.3% from a year earlier and up 6.7% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Total current liabilities amounted to 5.5% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +6.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 14.94M USD
- Year-over-year change
- -35.0%
- 4-year CAGR
- -32.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.94M | -35.0% |
| FY2024 | 2024-12-31 | 22.98M | -66.3% |
| FY2023 | 2023-12-31 | 68.21M | +172.0% |
| FY2022 | 2022-12-31 | 25.08M | -65.3% |
| FY2021 | 2021-12-31 | 72.25M | — |
Total Current Liabilities vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +6.3% is the 5th highest of 10, against a peer median of +2.3%.
- Total current liabilities amounts to 5.5% of total assets for RNAC, versus a peer median of 13.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €77.35M EUR | -35.9% | +36.1% | 31.1% | |
| Mar 2026 | $21.65M USD | -0.9% | +28.7% | 27.1% | |
| Mar 2026 | $16.29M USD | -9.8% | — | 489.1% | |
| Mar 2026 | $15.95M USD | +6.3% | -15.9% | 5.5% | |
| Mar 2026 | $13.69M USD | -11.6% | -3.4% | 13.6% | |
| Mar 2026 | $11.6M USD | +94.2% | +160.7% | 11.8% | |
| Mar 2026 | $11.6M USD | +106.6% | -16.4% | 11.6% | |
| Mar 2026 | $9.59M USD | +14.5% | +31.6% | 13.3% | |
| Mar 2026 | $8.34M USD | +2.3% | +5.4% | 4.7% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $7.39M USD | +235.8% | +10.8% | 5.1% |
| Peer median (excluding RNAC) | — | +2.3% | +19.7% | 13.3% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.06M | 106.44M | 76.91M | 212.61M | 125.14M |
| Short-term Investments | 14M | 28.16M | 0 | 0 | 0 |
| Net Receivables | 9.91M | 9.86M | 8.85M | 872K | 1.12M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.68M | 4.97M | 3.14M | 3.02M |
| Total Current Assets | 144.44M | 148.14M | 90.73M | 216.63M | 129.28M |
| Property, Plant & Equipment (Net) | 11.97M | 14.41M | 12.18M | 15.45M | 17.79M |
| Goodwill | 0 | 0 | 48.16M | 48.16M | 48.16M |
| Intangible Assets | 0 | 0 | 150.6M | 150.6M | 0 |
| Long-term Investments | 2M | 2M | 2M | 2M | 1.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.47M | 1.34M | 1.38M | 2.19M | 99.45M |
| Total Non-current Assets | 15.44M | 17.75M | 214.32M | 218.4M | 167.14M |
| Total Assets | 159.88M | 165.89M | 305.05M | 435.02M | 296.41M |
| Account Payables | 224K | 316K | 3.15M | 288K | 1.29M |
| Short-term Debt | 5.96M | 8.48M | 0 | 0 | 4.15M |
| Tax Payables | 601K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 53.88M | 593K | 2.31M | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 56.19M | 7.76M | 5.51M |
| Total Current Liabilities | 72.25M | 25.08M | 68.21M | 22.98M | 14.94M |
| Long-term Debt | 19.67M | 17.79M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 322.08M | 16.14M | 6.95M |
| Deferred Revenue (Non-current) | 11.42M | 0 | 3.54M | 0 | 0 |
| Other Non-current Liabilities | 25.42M | 19.14M | 342.62M | 391.58M | 392.24M |
| Total Non-current Liabilities | 65.11M | 46.98M | 677.03M | 418.85M | 407.71M |
| Total Liabilities | 137.36M | 72.06M | 745.23M | 441.83M | 422.65M |
| Common Stock | 12K | 15K | 16K | 3K | 3K |
| Retained Earnings | (430.32M) | (394.94M) | (614.65M) | (692.07M) | (822.37M) |
| Accumulated OCI | (4.57M) | (4.56M) | (4.6M) | (4.62M) | (4.58M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.52M | 93.83M | (440.18M) | (6.8M) | (126.24M) |
| Total Debt | 35.28M | 37.93M | 10.96M | 13.98M | 12.68M |
| Net Debt | (78.78M) | (68.51M) | (65.96M) | (198.63M) | (112.46M) |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.